Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06678841 · ClinicalTrials.gov registry record · NA
ELEVATE-HFpEF Clinical Study
A NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Recruiting
- Registry status
- NA
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT06678841: Recruiting NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT06678841 is a NA study of Heart Failure With Preserved Ejection Fraction (HFPEF) that is actively recruiting participants, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 700 participants, above the 142-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (393% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06678841, a NA study of Heart Failure With Preserved Ejection Fraction (HFPEF), is actively recruiting participants, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- RECRUITING
- Registry status
- NA
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
Primary Outcome
Cardiovascular mortality, urgent heart failure events, and ODI heart failure events will be collected as they occur. The Kansas City Cardiomyopathy Questionnaire (KCCQ); (range of score is 0 to 100), 6-minute walk test (distance in meters), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (picograms per milliliter, pg/mL) will be collected at Baseline and the 12-months visit. Treatment and control groups will be compared using a win ratio.
Conditions Studied
Interventions
- DEVICE Personalized cardiac pacing
Study Locations (20)
Other
- Ordensklinikum Linz GmbH / Elisabethinen - Linz
- Universitair Ziekenhuis Antwerpen - Edegem
- Centre Hospitalier Universitaire Besancon - Hôpital Jean Minjoz - Besançon
Ohio
- The Ohio State University Wexner Medical Center - Columbus
- Mount Carmel East - Columbus
Connecticut
- Hartford Hospital - Hartford
Florida
- Cardiovascular Institute of Northwest Florida - Panama City
Georgia
- Emory University - Atlanta
Iowa
- Iowa Heart Center - Des Moines
Louisiana
- Cardiovascular Institute of the South - Houma
Missouri
- Saint Lukes Mid America Heart Institute - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2029-02 |
| Phase | NA |
What NCT06678841 shows while recruiting
NCT06678841 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 142-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (393% higher).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction (HFPEF) appearing as the primary indexed condition, and to 1 intervention - of which Personalized cardiac pacing is the first listed.
NCT06678841 names 20 study sites across 17 states, led by Other, Ohio, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06678841 about?
NCT06678841 is a clinical study titled "ELEVATE-HFpEF Clinical Study". ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection ...
What is the current status of trial NCT06678841?
This trial is currently recruiting. It is a NA study. The enrollment target is 700 participants. The study started on 2025-07-09. Estimated completion is 2029-02.
What conditions does trial NCT06678841 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFPEF).
What interventions are being tested in trial NCT06678841?
The interventions under investigation include: Personalized cardiac pacing (DEVICE).
Who is sponsoring clinical trial NCT06678841?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06678841 being conducted?
This trial has 20 study locations across Connecticut, Florida, Georgia, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction (HFPEF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06678841's enrollment target sits among peer trials
700 1st of 9 higher than 9 of 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction (HFPEF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
RECRUITING · NA
-
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
ACTIVE NOT RECRUITING · NA
-
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
RECRUITING
-
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 1
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI